NATRIURETIC PEPTIDES - THEIR IMPORTANCE IN DIAGNOSTICS AND TREATMENT OF PATHOLOGICAL PROCESSESS
Keywords:
natriuretic peptides, heart failure, hypertension, neprilysin inhibitors, angiotensin II, Renin-angiotensine aldosterone system, sympathoadrenal systemAbstract
Recent studies have shown that natriuretic peptides (NUP) play a significant role in the early diagnosis of heart failure. This article is dedicated to elucidating the pathophysiological foundations of changes in the types and levels of NPO in various diseases (heart failure, arterial hypertension, and kidney dysfunction). Along with this, the content of NUP in patients of different ages and its significance in diagnosis were discussed. The results of scientific research dedicated to the modification of NUP have confirmed that it plays an important role not only in diagnosis, but also in treatment.
References
Del Ry S, Cabiati M, Clerico A. Natriuretic peptide system and the heart. Front Horm Res. 2014;43:134-43. doi:10.1159/000360597.
Huffman MD, Prabhakaran D. Heart failure: epidemiology and prevention in India. Natl Med J India. 2010;23:283-8. PMID: 21250584.
Weiwei C, Runlin G, Lisheng L, et al. Outline of the report on cardiovascular diseases in China, 2014. Eur Heart J. 2016;18(Suppl.):F2-11. doi:10.1093/eurheartj/suw030.
Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017;135:e146-603. doi:10.1161/ CIR.0000000000000485.
Bloom MW, Greenberg B, Jaarsma T, et al. Heart failure with reduced ejection fraction. Nat Rev Dis Primers. 2017;3:17058. doi:101038/nrdp.2017.58.
Cao ZP, Xue JJ, Zhang Y, et al. Differential expression of B-type natriuretic peptide between left and right ventricles, with particular regard to sudden cardiac death. Mol Med Rep. 2017;16:4763-9. doi:10.3892/mmr.2017.7136.
Kato J. Natriuretic peptides. In: Caplan M. (Ed.), Reference Module in Biomedical Sciences, Elsevier: London, UK, 2014. doi:101016/B978-0-12-801238-3.03972-6.
Ogawa T, de Bold AJ. The heart as an endocrine organ. Endocr Connect. 2014;3:R31-44. doi:10.1530/EC-14-0012.
Visseren FLJ, Mach F, Smulders YM, et al.; ESC Scientific Document Group; ESC National Cardiac Societies. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337. doi: 10.1093/ eurheartj/ehab484.
Fu S, Ping P, Wang F, Luo L. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J Biol Eng. 2018;12:2. doi:101186/s13036-017-0093-0.
Chang KW, Hsu JC, Toomu A, et al. Clinical Applications of Biomarkers in Atrial Fibrillation. Am J Med. 2017;130:1351-7. doi:101016/j.amjmed.2017.08.003.
Mueller C, McDonald K, de Boer RA, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(6):715-31. doi:10.1002/ejhf.1494.
Kato J, Etoh T, Kitamura K, Eto T. Atrial and brain natriuretic peptides as markers of cardiac load and volume retention in primary aldosteronism. Am J Hypertens. 2021;18:354-57. doi:10.1016/j.amjhyper.2021.09.016.
Рахимова М. Э., Гадаев А. Г., Туракулов Р. И., Гадаева Н. А. Состояние почечной гемодинамики у больных с ХСН протекающий с ХСН. Международный научно практический журнал «Глобальная наука и иновация 2020» центральная Азия. С.90-93.
Рахимова М. Э., Туракулов Р. И. и соавторы. Оценка биохимических показателей крови и почечной дисфункции у больных с ХСН. Медична та клінічна хімія. 2020. Т. 22. № 3. С 32-38.
